研究将GLP-1减重药物与稀有视力问题(包括NAION)联系起来,引发医生警告。 Study links GLP-1 weight loss drugs to rare vision issues, including NAION, prompting doctor warnings.

最近对JAMA Ophthalmolology的一项研究报告了包括NAION在内的9个罕见的视力问题案例,涉及服用GLP-1重量减量药物的人,如Semagluttide(Wegovy/Ozempic)和tirzepatide(Mounjaro/Zepbound)。 A recent study in JAMA Ophthalmology reported nine rare cases of vision issues, including NAION, in people taking GLP-1 weight loss drugs like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). 虽然研究发现药物和视力问题之间有联系,但不清楚药物是直接引起这些问题,还是糖尿病或心脏病等其他基本病症也起了作用。 While the study found a link between the medications and vision problems, it is unclear if the drugs directly cause these issues or if other underlying conditions like diabetes or heart disease play a role. 研究人员建议病人在服用这些药物时,如果视力发生变化,应立即去看医生。 Researchers advise patients to see a doctor immediately if they experience vision changes while on these medications.